These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

497 related articles for article (PubMed ID: 32290478)

  • 1. Natural Killer Cells: Tumor Surveillance and Signaling.
    Meza Guzman LG; Keating N; Nicholson SE
    Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32290478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficient Killing of Murine Pluripotent Stem Cells by Natural Killer (NK) Cells Requires Activation by Cytokines and Partly Depends on the Activating NK Receptor NKG2D.
    Gröschel C; Hübscher D; Nolte J; Monecke S; Sasse A; Elsner L; Paulus W; Trenkwalder C; Polić B; Mansouri A; Guan K; Dressel R
    Front Immunol; 2017; 8():870. PubMed ID: 28890717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natural killer cells as a promising therapeutic target for cancer immunotherapy.
    Kim N; Lee HH; Lee HJ; Choi WS; Lee J; Kim HS
    Arch Pharm Res; 2019 Jul; 42(7):591-606. PubMed ID: 30895524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural Killer Cell Immunomodulation: Targeting Activating, Inhibitory, and Co-stimulatory Receptor Signaling for Cancer Immunotherapy.
    Chester C; Fritsch K; Kohrt HE
    Front Immunol; 2015; 6():601. PubMed ID: 26697006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNAM-1 and the TIGIT/PVRIG/TACTILE Axis: Novel Immune Checkpoints for Natural Killer Cell-Based Cancer Immunotherapy.
    Sanchez-Correa B; Valhondo I; Hassouneh F; Lopez-Sejas N; Pera A; Bergua JM; Arcos MJ; Bañas H; Casas-Avilés I; Durán E; Alonso C; Solana R; Tarazona R
    Cancers (Basel); 2019 Jun; 11(6):. PubMed ID: 31234588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic potential and challenges of natural killer cells in treatment of solid tumors.
    Gras Navarro A; Björklund AT; Chekenya M
    Front Immunol; 2015; 6():202. PubMed ID: 25972872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Designing multivalent proteins based on natural killer cell receptors and their ligands as immunotherapy for cancer.
    Smits NC; Coupet TA; Godbersen C; Sentman CL
    Expert Opin Biol Ther; 2016 Sep; 16(9):1105-12. PubMed ID: 27248342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Role of the Cytoskeleton in Regulating the Natural Killer Cell Immune Response in Health and Disease: From Signaling Dynamics to Function.
    Ben-Shmuel A; Sabag B; Biber G; Barda-Saad M
    Front Cell Dev Biol; 2021; 9():609532. PubMed ID: 33598461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natural killer group 2D receptor and its ligands in cancer immune escape.
    Duan S; Guo W; Xu Z; He Y; Liang C; Mo Y; Wang Y; Xiong F; Guo C; Li Y; Li X; Li G; Zeng Z; Xiong W; Wang F
    Mol Cancer; 2019 Feb; 18(1):29. PubMed ID: 30813924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human NK cells: From surface receptors to clinical applications.
    Moretta L; Pietra G; Vacca P; Pende D; Moretta F; Bertaina A; Mingari MC; Locatelli F; Moretta A
    Immunol Lett; 2016 Oct; 178():15-9. PubMed ID: 27185471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insufficient natural killer cell responses against retroviruses: how to improve NK cell killing of retrovirus-infected cells.
    Littwitz-Salomon E; Dittmer U; Sutter K
    Retrovirology; 2016 Nov; 13(1):77. PubMed ID: 27821119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natural killer cell tolerance licensing and other mechanisms.
    Jonsson AH; Yokoyama WM
    Adv Immunol; 2009; 101():27-79. PubMed ID: 19231592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Key Activating and Inhibitory Ligands Involved in the Mobilization of Natural Killer Cells for Cancer Immunotherapies.
    Karmakar S; Pal P; Lal G
    Immunotargets Ther; 2021; 10():387-407. PubMed ID: 34754837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imbalance of NKG2D and its inhibitory counterparts: how does tumor escape from innate immunity?
    Zhang C; Zhang J; Wei H; Tian Z
    Int Immunopharmacol; 2005 Jul; 5(7-8):1099-111. PubMed ID: 15914316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Markers and function of human NK cells in normal and pathological conditions.
    Del Zotto G; Marcenaro E; Vacca P; Sivori S; Pende D; Della Chiesa M; Moretta F; Ingegnere T; Mingari MC; Moretta A; Moretta L
    Cytometry B Clin Cytom; 2017 Mar; 92(2):100-114. PubMed ID: 28054442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification and functional analysis of ligands for natural killer cell activating receptors in colon carcinoma.
    Zhang Z; Su T; He L; Wang H; Ji G; Liu X; Zhang Y; Dong G
    Tohoku J Exp Med; 2012 Jan; 226(1):59-68. PubMed ID: 22189020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Co-Activation of Cultured Human Natural Killer Cells: Enhanced Function and Decreased Inhibition.
    Urlaub D; Bhat R; Messmer B; Watzl C
    J Toxicol Environ Health A; 2016; 79(22-23):1078-1084. PubMed ID: 27924718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitory receptor-mediated regulation of natural killer cells.
    Alari-Pahissa E; Grandclément C; Jeevan-Raj B; Held W
    Crit Rev Immunol; 2014; 34(6):455-65. PubMed ID: 25597309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular checkpoints controlling natural killer cell activation and their modulation for cancer immunotherapy.
    Kwon HJ; Kim N; Kim HS
    Exp Mol Med; 2017 Mar; 49(3):e311. PubMed ID: 28360428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natural killer cell receptors: alterations and therapeutic targeting in malignancies.
    Konjević G; Vuletić A; Mirjačić Martinović K
    Immunol Res; 2016 Feb; 64(1):25-35. PubMed ID: 26374324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.